These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 30649377)

  • 41. Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma.
    Kweldam CF; Kümmerlin IP; Nieboer D; Verhoef EI; Steyerberg EW; Incrocci L; Bangma CH; van der Kwast TH; Roobol MJ; van Leenders GJ
    Eur J Cancer; 2016 Oct; 66():26-33. PubMed ID: 27522247
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Similar Recurrence Rate Between Gleason Score of Six at Positive Margin and Negative Margin After Radical Prostatectomy.
    Kano H; Kadono Y; Kadomoto S; Iwamoto H; Yaegashi H; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Ikeda H; Mizokami A
    Anticancer Res; 2021 Jan; 41(1):509-516. PubMed ID: 33419850
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer.
    Servoll E; Saeter T; Vlatkovic L; Lund T; Nesland J; Waaler G; Axcrona K; Beisland HO
    BJU Int; 2012 May; 109(10):1489-94. PubMed ID: 21933333
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Revised Gleason grading system is a better predictor of indolent prostate cancer at the time of diagnosis: retrospective clinical-pathological study on matched biopsy and radical prostatectomy specimens.
    Giunchi F; Brunocilla E; Borghesi M; Rizzi S; Ricci MS; Romagnoli D; Martorana G; Schiavina R; Fiorentino M
    Clin Genitourin Cancer; 2014 Oct; 12(5):325-9. PubMed ID: 24583160
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy.
    Thomsen FB; Folkvaljon Y; Brasso K; Loeb S; Robinson D; Egevad L; Stattin P
    J Surg Oncol; 2016 Nov; 114(6):664-670. PubMed ID: 27511833
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of perioperative leukocytosis in patients undergoing robot-assisted radical prostatectomy: effects of Gleason score and race.
    Patel T; Wambi C; Berg WT; Bergman A; Shapiro EY; Badani KK
    J Endourol; 2013 Dec; 27(12):1463-7. PubMed ID: 24074199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Favorable risk factors in patients with positive surgical margin after robot-assisted radical prostatectomy.
    Ha YS; Kang DI; Kim JH; Joung JY; Yu J; Parihar JS; Salmasi AH; Horie S; Kim WJ; Yi Kim I
    Can J Urol; 2014 Jun; 21(3):7290-7. PubMed ID: 24978359
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer.
    Hamada R; Nakashima J; Ohori M; Ohno Y; Komori O; Yoshioka K; Tachibana M
    Int J Clin Oncol; 2016 Jun; 21(3):595-600. PubMed ID: 26585896
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer.
    Taguchi S; Shiraishi K; Fukuhara H; Nakagawa K; Morikawa T; Naito A; Kakutani S; Takeshima Y; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Homma Y
    Int J Clin Oncol; 2016 Oct; 21(5):975-980. PubMed ID: 27098807
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Surgical and oncological outcomes in patients with a preoperative PSA value <4 ng/ml undergoing robot-assisted radical prostatectomy.
    Zugor V; Labanaris AP; Bauer RM; Witt JH
    Anticancer Res; 2012 May; 32(5):2079-83. PubMed ID: 22593492
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Robot-assisted radical prostatectomy in the treatment of patients with clinically high-risk localized and locally advanced prostate cancer: single surgeons functional and oncologic outcomes.
    Shin TY; Lee YS
    BMC Urol; 2022 Apr; 22(1):49. PubMed ID: 35379195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
    Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
    Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of pathological factors on oncological outcomes after robot-assisted radical prostatectomy for localized prostate cancer: Results of a prospective study.
    Kozal S; Peyronnet B; Cattarino S; Seisen T; Comperat E; Vaessen C; Mozer P; Renard-Penna R; Cussenot O; Rouprêt M; Drouin SJ
    Urol Oncol; 2015 Jul; 33(7):330.e1-7. PubMed ID: 25998747
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictive Factors for Early Biochemical Recurrence Following Robot-assisted Radical Prostatectomy.
    Mitsunari K; Fukushima H; Kurata H; Harada J; Nakamura Y; Matsuo T; Ohba K; Mochizuki Y; Imamura R
    Anticancer Res; 2024 Jul; 44(7):3149-3154. PubMed ID: 38925837
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical impact of prostate biopsy undergrading in an academic and community setting.
    Mortezavi A; Keller EX; Poyet C; Hermanns T; Saba K; Randazzo M; Fankhauser CD; Wild PJ; Moch H; Sulser T; Eberli D
    World J Urol; 2016 Oct; 34(10):1481-90. PubMed ID: 26931560
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Robotic-assisted radical prostatectomy in men ≤50 years of age. Surgical, oncological and functional outcomes.
    Labanaris AP; Zugor V; Witt JH
    Anticancer Res; 2012 May; 32(5):2097-101. PubMed ID: 22593495
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
    [TBL] [Abstract][Full Text] [Related]  

  • 59. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of Gleason score on biochemical recurrence in patients with pT3aN0/Nx prostate cancer with positive surgical margins: a multicenter study from the Prostate Cancer Research Committee.
    Song W; Lee DH; Jeon HG; Jeong BC; Seo SI; Lee HM; Choi HY; Kim JW; Lee S; Byun SS; Jeong CW; Kwak C; Cho JS; Ahn H; Jeon SS
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2393-2400. PubMed ID: 28823006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.